Citations

Clear

1031 citation(s) found for "Clark, AS".

Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care
Navari, Rudolph M. , Ruddy, Kathryn J. , LeBlanc, Thomas W. , Clark-Snow, Rebecca, Wickham, Rita , Binder, G. , Coberly, Tammy Bratton, Schmerold, Luke, Roeland, Eric , Leblanc, Thomas , Roeland, Eric J , Potluri, Ravi C.

Mayo Clinic

JCO Oncology Practice | December 4, 2019 | Volume: 16 | Issue: 2 | Pages: e132-e138

10.1200/jop.19.00457 | PMID 31800352 Get It

PURPOSE: After ASCO and National Comprehensive Cancer Network guideline recommendations for triple antiemetic prophylaxis for carboplatin area under the curve (AUC) ≥ 4, and the publication of studies documenting avoidable acute care after chemotherapy involving nausea and vomiting (NV) and other toxicities, we studied clinician adherence to the guideline change and assessed avoidable acute-care use. METHODS: Using a large electronic health record database, we evaluated antiemetic prophylaxis as recommended in the guidelines and post-chemotherapy avoidable acute-care use (defined as involving any of NV or 8 other toxicities) for patients initiating carboplatin or other chemotherapy from October 2012 to August 2018. RESULTS: We identified 11,554 carboplatin courses. After the guideline change adding neurokinin-1 receptor antagonists (RAs) for carboplatin AUC ≥ 4, its use rose to 20% of courses from the prior average of 16%; virtually all courses also included a 5-HT3 RA plus dexamethasone. We found avoidable acute care in 23% of courses; one quarter of these events were associated with NV. Acute care rates after carboplatin mirrored those after other highly emetogenic chemotherapy or oxaliplatin and exceeded those after other chemotherapy regimens. The > 80% shortfall in adherence may have been caused by low awareness or acceptance of the guideline change and/or by poor awareness of avoidable acute-care use after carboplatin. CONCLUSION: Neurokinin-1 RA prophylaxis for carboplatin AUC ≥ 4 remains low and largely unchanged despite National Comprehensive Cancer Network and ASCO 2017 recommendations for inclusion. NV and avoidable acute care involving NV seen after carboplatin were consistent with other highly emetogenic chemotherapy. Clinician action is required to remediate incomplete prophylaxis and to no longer place patient outcomes, resources for cancer treatment, and clinician reimbursement at risk.
Primary reverse shoulder arthroplasty in patients older than 80 years of age
Samuelsen, Brian T. , Assenmacher, Andrew T. , Cofield, Robert H. , Sperling, John W. , Clark, Nicholas J. , Alentorn-Geli, Eduard, Sanchez-Sotelo, Joaquin, Clark, Nicholas , Alentorn‐Geli, Eduard , Sánchez‐Sotelo, Joaquín

Mayo Clinic

The Bone & Joint Journal | December 2, 2019 | Volume: 101-B | Issue: 12 | Pages: 1520-1525

10.1302/0301-620x.101b12.bjj-2018-1571.r2 | PMID 31787000 Get It

Aims Reverse shoulder arthroplasty (RSA) reliably improves shoulder pain and function for a variety of indications. However, the safety and efficacy of RSA in elderly patients is largely unknown. The purpose of this study was to report the mortality, morbidity, complications, reoperations, and outcomes of primary RSA in patients aged > 80 years. Patients and Methods Between 2004 and 2013, 242 consecutive primary RSAs were performed in patients aged > 80 years (mean 83.3 years (sd 3.1)). Of these, 53 were lost to follow-up before two years and ten had died within two years of surgery, leaving 179 for analysis of survivorship, pain, motion, and strength at a minimum of two years or until revision surgery. All 242 patients were considered for the analysis of 90-day, one-year, and overall mortality, medical complications (90-day and overall), surgical complications, and reoperations. The indications for surgery included rotator cuff arthropathy, osteoarthritis, fracture, the sequela of trauma, avascular necrosis, and rheumatoid arthritis. A retrospective review of the medical records was performed to collect all variables. Survivorship free of revision surgery was calculated at two and five years. Results One patient (0.4%) died within the first 90 days. A total of 45 patients (19%) were known to have died at the time of the final follow-up, with a median time to death of 67.7 months (interquartile range 40.4 to 94.7) postoperatively. Medical complications occurred in six patients (3%) and surgical complications occurred in 21/179 patients (12%). Survivorship free from revision was 98.9% at two years and 98.3% at five years; survivorship free from loosening was 99.5% at final follow-up. The presence of peripheral vascular disease correlated with a higher complication rate. Conclusion Primary RSA was safe and effective in patients aged > 80 years, with a relatively low rate of medical and surgical complications. Thus, age alone should not be a contraindication to primary RSA in patients aged > 80 years. However, a careful evaluation of comorbidities is required in this age group when considering primary RSA. Cite this article: Bone Joint J 2019;101-B:1520–1525
A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience
Rieck, Thomas , Lee, Jennifer R., Ferguson, Jennifer A., Peterson, Laura A., Lillie, Charlene M Martin, Clark, Matthew M. , Bauer, Brent A. , Rieck, Thomas M , Martin Lillie, Charlene M, Limburg, Paul J.

Mayo Clinic

Global Advances in Health and Medicine | November 29, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119892597 | PMID 31827983 Get It

Objectives The aim of this study was to compare the stress reduction effects of spending 25 minutes reclining in a SolTec™ Lounge between 2 intervention groups. Group 1 experienced the Lounge with multilayered music on an external speaker, while group 2 experienced the Lounge with multilayered music and synchronous vibration and magnetic stimulation from within the chair. Subjects In total, 110 participants with a self-reported stress level of 4 or higher on a 0- to 10-point scale were recruited from the local community including employees. Participants were randomized into receiving 1 of the 2 interventions. There were no significant differences between the group’s average stress levels prior to the interventions. Interventions Both groups received a 25-minute session in a dimly lit, quiet area on the Lounge with multilayered music. The second group also received vibration and magnetic stimulation that were synchronized with the music. Design Current stress level as well as ratings or feelings of anxiety, tenseness, energy, focus, happiness, relaxation, nervousness, creativeness, and being rested were recorded before and after the session. Results Both groups of participants reported equivalent decreased feelings of stress after using the Lounge. Participants receiving the synchronous multilayered music, vibration, and magnetic stimulation did report significantly reduced feelings of tenseness, feeling more relaxed, and feeling more creative when compared with the group that received music only. Conclusion Spending 25 minutes in the SolTec™ Lounge with multilayered music is an effective way to reduce self-reported stress in individuals who self-report having a high stress level. If confirmed by future studies, including synchronous vibration and magnetic stimulation with the multilayered music might be an effective stress reduction strategy.
Immunohistochemistry and Special Stains in Medical Liver Pathology
Clark, Ian A. , Clark, Ian, Clark, Ian, Torbenson, Michael

Mayo Clinic

Advances in Anatomic Pathology | November 27, 2019 | Volume: 24 | Issue: 2 | Pages: 99-109

10.1097/pap.0000000000000139 | PMID 28181953 Get It

Histochemical and immunostains are routinely used to evaluate medical liver biopsy specimens. The use of these special stains allows the identification of more clinically important information than is available on hematoxylin and eosin stains alone. These special stains are important for evaluating active and chronic injury and for establishing a specific diagnosis. The skillful use of these stains greatly improves patient care. Information on the use of special stains can be scattered in different sources, making the information hard to access. In this article, the use of special stains in medical liver biopsies is concisely reviewed.
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration
Olney, Nicholas , Ong, Elise, Goh, Sheng‐Yang M., Bajorek, Lynn, Dever, Reilly, Staffaroni, Adam M. , Bock, Meredith , Chiang, Kevin, Ljubenkov, Peter A. , Kornak, John , Heuer, Hilary W. , Rascovsky, Katya, Wolf, Amelia, Bove, Jessica, Bordelon, Yvette , Brannelly, Patrick , Brushaber, Danielle , Caso, Christine, Coppola, Giovanni , Dickinson, Susan, Domoto‐Reilly, Kimiko , Faber, Kelly, Ferrall, Jessica, Fields, Julie A. , Fishman, Ann, Foroud, Tatiana M., Forsberg, Leah K. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kraft, Ruth, Kremers, Walter K. , Kukull, Walter A. , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott M., McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Len, Potter, Madeleine, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Boxer, Adam L. , Rosen, Howard J. , consortia, on behalf of the ARTFL and LEFFTDS, Gearhart, Debra J, Boeve, Brad F, Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Cobigo, Yann , Wang, Ping , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Jones, David T. , Kerwin, Diana , Knopman, David S. , Lapid, Maria I. , Litvan, Irene , Potter, Madeleine, Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , consortia, on behalf of the ARTFL and LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | November 26, 2019 | Volume: 16 | Issue: 1 | Pages: 49-59

10.1016/j.jalz.2019.08.196 | PMID 31784375 Get It

AbstractIntroductionThe Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects longitudinal studies were designed to describe the natural history of familial‐frontotemporal lobar degeneration due to autosomal dominant mutations.MethodsWe examined cognitive performance, behavioral ratings, and brain volumes from the first time point in 320 MAPT, GRN, and C9orf72 family members, including 102 non–mutation carriers, 103 asymptomatic carriers, 43 mildly/questionably symptomatic carriers, and 72 carriers with dementia.ResultsAsymptomatic carriers showed similar scores on all clinical measures compared with noncarriers but reduced frontal and temporal volumes. Those with mild/questionable impairment showed decreased verbal recall, fluency, and Trail Making Test performance and impaired mood and self‐monitoring. Dementia was associated with impairment in all measures. All MAPT carriers with dementia showed temporal atrophy, but otherwise, there was no single cognitive test or brain region that was abnormal in all subjects.DiscussionImaging changes appear to precede clinical changes in familial‐frontotemporal lobar degeneration, but specific early clinical and imaging changes vary across individuals.
Acute care and hydration due to chemotherapy-induced nausea and vomiting (CINV) among patients receiving NEPA prophylaxis for anthracycline + cyclophosphamide (AC).
Roeland, Eric , Navari, Rudolph M. , Ruddy, Kathryn J. , LeBlanc, Thomas W. , Clark-Snow, Rebecca, Wickham, Rita S., Binder, G. , Bailey, William L., Leblanc, Thomas , Roeland, Eric J , Schwartzberg, Lee Steven

Mayo Clinic

Journal of Clinical Oncology | November 25, 2019 | Volume: 37 | Issue: 31_suppl | Pages: 112-112

10.1200/jco.2019.37.31_suppl.112 Get It

112 Background: In the US, the CMS OP-35 oncology outcome measure deems 30-day post-chemotherapy acute care involving nausea and emesis (NV) or 8 other toxicities as avoidable, with studies showing 15% of > 2500 patients receiving anthracycline + cyclophosphamide (AC)-based chemotherapy had avoidable acute care, of which 32% involved NV. Our aim was to evaluate resource use (emergency department [ED] visits, inpatient admissions [IP], or hydration) in a prospective trial of women with breast cancer who received combination netupitant/palonosetron (NEPA) + dexamethasone (DEX) for CINV prophylaxis for AC-based chemotherapy. Methods: Women initiating AC received oral or IV NEPA + DEX. Pre-specified endpoints included safety, complete response, acute care (ED/IP), unplanned IV hydrations (as determined by investigator), days of CINV, and ≥3 days of CINV. We defined CINV as emesis or rescue drug use up to 5 days after AC, and defined concomitant ED/IP or hydrations in the same period as CINV-related. We limited our analysis to the first 2 cycles, the median duration in the NEPA study. Results: 402 patients received ≥1 cycle of AC and 391 completed 2 cycles. Nine patients had IP (none CINV-related), and 5 patients had a total of 6 ED visits (1 CINV-related). Three patients had a CINV-related unplanned hydration. Patients had ≥1 day of CINV in 172 of 793 cycles (21.7%); of these, the majority had symptom duration for 1-2 days, while 78 (9.8%) had ≥3 days of CINV in a cycle. Conclusions: In this prospective CINV prophylaxis study in women receiving AC chemotherapy, < 1% of women receiving NEPA + DEX required acute care for CINV and < 1% required unplanned hydrations for CINV. These rates are below previously reported CINV-related acute care rates for AC suggesting NEPA may help avoid CINV-related acute care. Clinical trial information: NCT03403712.
NIMG-26. EVALUATING THE DAYS GAINED RESPONSE METRIC IN CLINICAL TRIALS USING BEVACIZUMAB PLUS ADDITIONAL AGENTS FOR RECURRENT GLIOBLASTOMA
Singleton, Kyle , Johnston, Sandra K. , Rickertsen, Cassandra , Anderson, S. Keith , León, Gustavo De , Whitmire, Scott A., Clark-Swanson, Kamala , Mrugała, Maciej M. , Porter, Alyx B. , Swanson, Kristin R. , Swanson, Kristin R , Leon, Gustavo De, Bendok, Bernard R. , Galanis, Evanthia

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi167-vi167

10.1093/neuonc/noz175.697 Get It

Abstract Determining effective therapies for patients with recurrent glioblastoma remains difficult especially in small early phase clinical trials. Currently utilized estimators of treatment response rely on two-dimensional measurements of tumor progression (e.g. RANO, RECIST, MacDonald) that have often fallen short in reliably connecting patients who respond with positive survival outcomes. This has prompted consideration of advanced imaging and volumetric measurements by the RANO working group and others. Our proposed approach, Days Gained (DG), uses volumetric measurements to calculate a personalized response metric based on change in tumor growth characteristics pre/post-treatment. DG has shown promise for connecting imageable treatment response with clinically meaningful (statistically significant) survival benefit when applied in upfront and recurrent therapy settings, even in the context of coincident bevacizumab treatment. In this study, we seek to consider a new cohort of patients receiving bevacizumab in combination with other novel therapies to distinguish any subpopulation of patients with meaningful response. In this work, we identified a subset of 16 patients from bevacizumab clinical trials with data available for DG analysis requiring serial imaging (T1Gd and FLAIR) prior to and after the first cycle of therapy. Each trial evaluated bevacizumab alone versus bevacizumab plus either dasatinib or TRC105 in recurrent disease. Discrimination of time to progression (TTP) was evaluated at DG thresholds identified from our prior analysis of patients treated with bevacizumab. Using previously identified DG thresholds for clinically significant treatment benefit, in our cohort, DG measured by serial FLAIR imaging was significant in predicting longer TTP (120 DG, p=0.014), but T1Gd DG scores did not attain significance (p=0.630). Given the limited insights in connecting response metrics to accurately predicted outcomes, these data further support the use of DG as a burgeoning marker of treatment response (or lack of response) that may be useful for more routine integration into clinical trials.
NIMG-61. USING MACHINE LEARNING TO BUILD RADIOMICS MODELS THAT DISTINGUISH REGIONS OF GLIOBLASTOMA RECURRENCE VS TUMOR PROGRESSION ON MRI
Save, Akshay , Singleton, Kyle , Clark-Swanson, Kamala , Mrugala, Maciej , Bruce, Jeffrey N. , Hu, Leland , Li, Jing , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Yoon, Hyunsoo , Hawkins‐Daarud, Andrea , Wang, Lujia , Bendok, Bernard R. , Wu, Teresa

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi175-vi175

10.1093/neuonc/noz175.730 Get It

Abstract Recurrent glioblastoma is challenging to distinguish from so called “treatment effect” on routine clinical imaging. Further, within tumor heterogeneity reveals that some regions can be histologically dominated by tumor progression whilst others can be dominated by secondary effects of treatment response. Apparent tumor progression on MRI can be very difficult to manage clinically as it is unclear the degree to which the imaging changes are actually tumor progression vs response to treatment (including inflammatory response and necrosis). In this analysis, we study a unique cohort of patients for whom image localized-biopsies reveal heterogeneity in response vs progression. Our dataset included 70 biopsy samples from 32 patients with GBM each histolopatholgically characterized for tumor abundance vs immune infiltrate. Six multiparametric MRI contrasts were available, including T1, T1gd, T2, FLAIR, SWI, and ADC. Images were co-registered. Radiomic (statistical + texture) features were extracted from the region of six image contrasts locally matched with each biopsy sample. Machine learning models were built to predict each biomarker using radiomic features. Leave-one-out cross validation was used to evaluate the prediction accuracy. Radiomic features were found to be informative to the prediction of biomarkers. ANOVA tests show significant improvement of using radiomic features compared with the null model. The prediction accuracy was higher when considering the biomarkers on a binary scale using the median as the cutoff than on a numerical scale. Spatially-informed radiomics models for tumor progression vs treatment effect are possible and can play an instrumental role in navigating confounding imaging changed common during treatment progression.
NIMG-30. REPRODUCIBLE RADIOMIC MAPPING OF TUMOR CELL DENSITY BY MACHINE LEARNING AND DOMAIN ADAPTATION
Singleton, Kyle , Clark-Swanson, Kamala , Mrugala, Maciej , Eschbacher, Jenny, Smith, Kris A. , Gonzalez, Ashlyn, Nespodzany, Ashley , Swanson, Kristin R. , Hu, Leland , Li, Jing , Swanson, Kristin R , Wang, Lujia , Yoon, Hyunsoo , Hawkins‐Daarud, Andrea , Bendok, Bernard R. , Nakaji, Peter , Baxter, Leslie C. , Wu, Teresa

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi167-vi167

10.1093/neuonc/noz175.700 Get It

Abstract BACKGROUND An important challenge in radiomics research is reproducibility. Images are collected on different image scanners and protocols, which introduces significant variability even for the same type of image across institutions. In the present proof-of-concept study, we address the reproducibility issue by using domain adaptation – an algorithm that transforms the radiomic features of each new patient to align with the distribution of features formed by the patient samples in a training set. METHOD Our dataset included 18 patients in training with a total of 82 biopsy sample. The pathological tumor cell density was available for each sample. Radiomic (statistical + texture) features were extracted from the region of six image contrasts locally matched with each biopsy sample. A Gaussian Process (GP) classifier was built to predict tumor cell density using radiomic features. Another 6 patients were used to test the training model. These patients had a total of 31 biopsy samples. The images of each test patient were purposely normalized using a different approach, i.e., using the CSF instead of the whole brain as the reference. This was to mimic the practical scenario of image source discrepancy between different patients. Domain adaptation was applied to each test patient. RESULTS Among the 18 training patients, the leave-one-patient-out cross validation accuracy is 0.81 AUC, 0.78 sensitivity, and 0.83 specificity. When the trained model was applied to the 6 test patients (purposely normalized using a different approach than that of the training data), the accuracy dramatically reduced to 0.39 AUC, 0.08 sensitivity, and 0.61 specificity. After using domain adaption, the accuracy improved to 0.68 AUC, 0.62 sensitivity, and 0.72 specificity. CONCLUSION We provide candidate enabling tools to address reproducibility in radiomics models by using domain adaption algorithms to account for discrepancy of the images between different patients.
NIMG-52. UNCERTAINTY QUANTIFICATION IN RADIOMICS
Singleton, Kyle , Clark-Swanson, Kamala , Smith, Kris A. , Eschbacher, Jenny, Gonzalez, Ashlyn, Nespodzany, Ashley , Patra, Devi Prasad, León, Gustavo De , Zimmerman, Richard S. , Porter, Alyx B. , Krishna, Chandan , Mrugala, Maciej , Swanson, Kristin R. , Hu, Leland , Swanson, Kristin R , Wang, Lujia , Yoon, Hyunsoo , Hawkins‐Daarud, Andrea , Nakaji, Peter , Baxter, Leslie C. , Bendok, Bernard R. , Leon, Gustavo De, Salomao, Marcela , Hoxworth, Joseph M. , Zhou, Yuxiang , Tran, Nhan L. , Wu, Teresa , Li, Jing

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi172-vi173

10.1093/neuonc/noz175.721 Get It

Abstract INTRODUCTION The quantification of intratumoral heterogeneity – through radiomics-based approaches - can help resolve the regionally distinct genetic drug targets that may co-exist within a single Glioblastoma (GBM) tumor. While this offers potential diagnostic value under the paradigm of individualized oncology, clinical decision-making must also consider the degree of uncertainty associated with each model. In this study, we evaluate the performance of a novel machine-learning (ML) algorithm, called Gaussian Process (GP) modeling, that can quantify the impact of multiple sources of uncertainty in ML model development and prediction accuracy, including variabilities in the copy number measurement, radiomics features, training sample characteristics, and training sample size. METHOD We collected 95 image-localized biopsies from 25 primary GBM patients. We coregistered stereotactic locations with preoperative multi-parametric MRI features (conventional MRI, DSC perfusion, Diffusion Tensor Imaging) to generate spatially matched pairs of MRI and copy number variants (CNV) for for each biopsy. We developed a Gaussian Process (GP) model to predict CNV for Epidermal Growth Factor Receptor (EGFR) based on MRI radiomic features in each patient. We used leave-one-patient-out cross validation to quantify prediction accuracy and model uncertainty. Spatial prediction and uncertainty (p-value) maps were overlaid to help visualize regional genetic variation of EGFR and uncertainty of the radiomic predictions. RESULT: The initial GP radiomics model for EGFR amplification (CNV > 3.5) produced a sensitivity of 0.8 and specificity of 0.8. Samples/regions associated with high uncertainty (p-value >0.05) correlated with either 1) extrapolation of radiomic features from the training set-defined feature space or 2) insufficient training samples in the feature space. CONCLUSION We present a ML-based model that quantifies spatial genetic heterogeneity in GBM, while also estimating model uncertainties that result from multi-source data variabilities. This approach lays the groundwork for prospective clinical integration of modeling-based diagnostic approaches in the paradigm of individualized medicine.